# Zentalis Pharmaceuticals, Inc.: financial statements, quarterly

ZNTL · Nasdaq · CIK 1725160 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zntl.md) · [Financials](/companies/zntl/financials.md) · [Filings](/companies/zntl/filings.md) · [Insiders](/companies/zntl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zntl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001725160-24-000173.md) | [0.0 d](/filings/0001725160-26-000014.md) | [40.6](/filings/0001725160-25-000105.md) | [0.0](/filings/0001725160-25-000149.md) | [0.0](/filings/0001725160-25-000161.md) | [26.9 d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-25-000105.md) | [0.0](/filings/0001725160-25-000149.md) | [0.0](/filings/0001725160-25-000161.md) | [0.0 d](/filings/0001725160-26-000014.md) | not reported | not reported |
| Research and development | $m | [46.8](/filings/0001725160-24-000173.md) | [51.6 d](/filings/0001725160-26-000014.md) | [49.6](/filings/0001725160-25-000105.md) | [48.4](/filings/0001725160-25-000149.md) | [36.8](/filings/0001725160-25-000161.md) | [33.0 d](/filings/0001725160-26-000014.md) | [27.2](/filings/0001725160-26-000042.md) | [27.6](/filings/0001725160-26-000062.md) | [23.0](/filings/0001725160-25-000161.md) | [29.5 d](/filings/0001725160-26-000014.md) | [28.7](/filings/0001725160-26-000042.md) | [35.2](/filings/0001725160-26-000062.md) |
| Operating income | $m | [(62.7)](/filings/0001725160-24-000173.md) | [(67.9) d](/filings/0001725160-26-000014.md) | [(24.8)](/filings/0001725160-25-000105.md) | [(65.1)](/filings/0001725160-25-000149.md) | [(51.4)](/filings/0001725160-25-000161.md) | [(49.8) d](/filings/0001725160-26-000014.md) | [(45.6)](/filings/0001725160-26-000042.md) | [(36.1)](/filings/0001725160-26-000062.md) | [(33.7)](/filings/0001725160-25-000161.md) | [(37.4) d](/filings/0001725160-26-000014.md) | [(37.9)](/filings/0001725160-26-000042.md) | [(44.4)](/filings/0001725160-26-000062.md) |
| Income tax | $m | [0.0](/filings/0001725160-24-000173.md) | [(0.1) d](/filings/0001725160-26-000014.md) | [0.1](/filings/0001725160-25-000105.md) | [0.3](/filings/0001725160-25-000149.md) | [(0.0)](/filings/0001725160-25-000161.md) | [(0.2) d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-26-000042.md) | [0.0](/filings/0001725160-26-000062.md) | [0.0](/filings/0001725160-25-000161.md) | [0.4 d](/filings/0001725160-26-000014.md) | [0.1](/filings/0001725160-26-000042.md) | [0.1](/filings/0001725160-26-000062.md) |
| Net income | $m | [(55.5)](/filings/0001725160-24-000173.md) | [(60.9) d](/filings/0001725160-26-000014.md) | [10.1](/filings/0001725160-25-000105.md) | [(88.3)](/filings/0001725160-25-000149.md) | [(40.2)](/filings/0001725160-25-000161.md) | [(47.5) d](/filings/0001725160-26-000014.md) | [(48.3)](/filings/0001725160-26-000042.md) | [(26.9)](/filings/0001725160-26-000062.md) | [(26.7)](/filings/0001725160-25-000161.md) | [(35.2) d](/filings/0001725160-26-000014.md) | [(35.4)](/filings/0001725160-26-000042.md) | [(42.3)](/filings/0001725160-26-000062.md) |
| Diluted EPS | $ per share | [(0.79)](/filings/0001725160-24-000173.md) | not reported | [0.14](/filings/0001725160-25-000105.md) | [(1.24)](/filings/0001725160-25-000149.md) | [(0.56)](/filings/0001725160-25-000161.md) | not reported | [(0.67)](/filings/0001725160-26-000042.md) | [(0.37)](/filings/0001725160-26-000062.md) | [(0.37)](/filings/0001725160-25-000161.md) | not reported | [(0.50)](/filings/0001725160-26-000042.md) | [(0.59)](/filings/0001725160-26-000062.md) |
| Basic EPS | $ per share | [(0.79)](/filings/0001725160-24-000173.md) | not reported | [0.14](/filings/0001725160-25-000105.md) | [(1.24)](/filings/0001725160-25-000149.md) | [(0.56)](/filings/0001725160-25-000161.md) | not reported | [(0.67)](/filings/0001725160-26-000042.md) | [(0.37)](/filings/0001725160-26-000062.md) | [(0.37)](/filings/0001725160-25-000161.md) | not reported | [(0.50)](/filings/0001725160-26-000042.md) | [(0.59)](/filings/0001725160-26-000062.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [111](/filings/0001725160-24-000173.md) | [28.0](/filings/0001725160-26-000014.md) | [37.6](/filings/0001725160-25-000105.md) | [37.0](/filings/0001725160-25-000149.md) | [41.3](/filings/0001725160-25-000161.md) | [33.9](/filings/0001725160-26-000014.md) | [41.9](/filings/0001725160-26-000042.md) | [37.6](/filings/0001725160-26-000062.md) | [39.1](/filings/0001725160-25-000161.md) | [36.0](/filings/0001725160-26-000062.md) | [31.9](/filings/0001725160-26-000042.md) | [24.8](/filings/0001725160-26-000062.md) |
| Current assets | $m | [528](/filings/0001725160-23-000196.md) | [497](/filings/0001725160-25-000067.md) | [504](/filings/0001725160-24-000107.md) | [440](/filings/0001725160-24-000158.md) | [400](/filings/0001725160-24-000173.md) | [386](/filings/0001725160-26-000014.md) | [343](/filings/0001725160-25-000105.md) | [312](/filings/0001725160-25-000149.md) | [288](/filings/0001725160-25-000161.md) | [253](/filings/0001725160-26-000062.md) | [218](/filings/0001725160-26-000042.md) | [181](/filings/0001725160-26-000062.md) |
| Total assets | $m | [586](/filings/0001725160-23-000196.md) | [552](/filings/0001725160-25-000067.md) | [557](/filings/0001725160-24-000107.md) | [492](/filings/0001725160-24-000158.md) | [451](/filings/0001725160-24-000173.md) | [430](/filings/0001725160-26-000014.md) | [384](/filings/0001725160-25-000105.md) | [352](/filings/0001725160-25-000149.md) | [327](/filings/0001725160-25-000161.md) | [289](/filings/0001725160-26-000062.md) | [253](/filings/0001725160-26-000042.md) | [215](/filings/0001725160-26-000062.md) |
| Current liabilities | $m | [58.9](/filings/0001725160-23-000196.md) | [69.4](/filings/0001725160-25-000067.md) | [54.8](/filings/0001725160-24-000107.md) | [66.7](/filings/0001725160-24-000158.md) | [54.9](/filings/0001725160-24-000173.md) | [52.7](/filings/0001725160-26-000014.md) | [49.4](/filings/0001725160-25-000105.md) | [39.0](/filings/0001725160-25-000149.md) | [37.2](/filings/0001725160-25-000161.md) | [36.6](/filings/0001725160-26-000062.md) | [35.2](/filings/0001725160-26-000042.md) | [37.6](/filings/0001725160-26-000062.md) |
| Total liabilities | $m | [104](/filings/0001725160-23-000196.md) | [114](/filings/0001725160-25-000067.md) | [98.7](/filings/0001725160-24-000107.md) | [109](/filings/0001725160-24-000158.md) | [96.3](/filings/0001725160-24-000173.md) | [93.2](/filings/0001725160-26-000014.md) | [88.6](/filings/0001725160-25-000105.md) | [77.2](/filings/0001725160-25-000149.md) | [74.4](/filings/0001725160-25-000161.md) | [72.8](/filings/0001725160-26-000062.md) | [70.4](/filings/0001725160-26-000042.md) | [71.7](/filings/0001725160-26-000062.md) |
| Shareholders' equity | $m | [482](/filings/0001725160-23-000196.md) | [437](/filings/0001725160-25-000067.md) | [459](/filings/0001725160-24-000107.md) | [383](/filings/0001725160-24-000158.md) | [354](/filings/0001725160-24-000173.md) | [337](/filings/0001725160-26-000014.md) | [295](/filings/0001725160-25-000105.md) | [274](/filings/0001725160-25-000149.md) | [253](/filings/0001725160-25-000161.md) | [216](/filings/0001725160-26-000062.md) | [183](/filings/0001725160-26-000042.md) | [144](/filings/0001725160-26-000062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(38.7) d](/filings/0001725160-24-000173.md) | [(40.6) d](/filings/0001725160-26-000014.md) | [(52.0)](/filings/0001725160-25-000105.md) | [(35.1) d](/filings/0001725160-25-000149.md) | [(44.0) d](/filings/0001725160-25-000161.md) | [(39.7) d](/filings/0001725160-26-000014.md) | [(32.6)](/filings/0001725160-26-000042.md) | [(34.7) d](/filings/0001725160-26-000062.md) | [(27.0) d](/filings/0001725160-25-000161.md) | [(30.9) d](/filings/0001725160-26-000014.md) | [(33.0)](/filings/0001725160-26-000042.md) | [(37.2) d](/filings/0001725160-26-000062.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001725160-24-000173.md) | [0.2 d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-25-000105.md) | [0.2 d](/filings/0001725160-25-000149.md) | [0.0 d](/filings/0001725160-25-000161.md) | [0.0 d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-26-000042.md) | [0.0 d](/filings/0001725160-26-000062.md) | [0.0 d](/filings/0001725160-25-000161.md) | [0.0 d](/filings/0001725160-26-000014.md) | [0.0](/filings/0001725160-26-000042.md) | [0.0 d](/filings/0001725160-26-000062.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.8](/filings/0001725160-23-000196.md) | [59.3](/filings/0001725160-24-000107.md) | [60.8](/filings/0001725160-24-000158.md) | [70.6](/filings/0001725160-24-000173.md) | [71.2](/filings/0001725160-25-000105.md) | [71.0](/filings/0001725160-25-000149.md) | [71.1](/filings/0001725160-25-000161.md) | [71.7](/filings/0001725160-26-000042.md) | [72.0](/filings/0001725160-26-000062.md) | [72.1](/filings/0001725160-25-000161.md) | [70.3](/filings/0001725160-26-000042.md) | [71.3](/filings/0001725160-26-000062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 71,671,914 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001725160-26-000062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.